Article
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2005
Antonescu Cristina R, Besmer Peter, Guo Tianhua, Arkun Knarik, Hom Glory, Koryotowski Beata, Leversha Margaret A, Jeffrey Philip D, Desantis Diann, Singer Samuel, Brennan Murray F, Maki Robert G, DeMatteo Ronald P
Abstract excerpt
Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA. Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST. It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy. To identify the mechanism of resistance, we studied 31 patients with...
Topics
- Adult
- Aged
- Aged, 80 and over
- Amino Acid Sequence
- Antineoplastic Agents
- Benzamides
- Blotting, Western
- DNA Mutational Analysis
- Drug Resistance, Neoplasm